CoChat

Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., Diamant, M. · 2013 · Diabetes, Obesity and Metabolism
Cited by 46

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Development of cardiovascular disease is one of the major complications of type 2 diabetes mellitus ( T2DM ). The chronic hyperglycaemic state is often accompanied by dyslipidaemia, hypertension, low‐grade systemic inflammation and oxidative stress which collectively result in a high risk of micro‐ and macrovascular complications. Current glucose‐lowering agents do not sufficiently address fore‐mentioned macrovascular‐risk factors. Recently, new therapeutic agents were introduced, based on the incretin hormone glucagon‐like peptide‐1 ( GLP ‐1), that is, the GLP ‐1 receptor agonists ( GLP‐1RA ) and dipeptidyl‐peptidase 4 ( DPP ‐4) inhibitors. Beside its effect on pancreatic insulin secretion, GLP ‐1 exerts several extra‐pancreatic effects such as slowing down gastric emptying, promoting satiety and reducing food intake and weight loss. Also, GLP ‐1 and GLP‐1RA were shown to improve cardiovascular‐risk profiles, by reducing body fat content, blood pressure, circulating lipids and inflammatory markers in patients with T2DM . This review summarizes the presently known evidence with regard to extra‐pancreatic effects of the incretin‐based agents, focusing on the actions that improve the cardiovascular‐risk profile. We present available data from clinical trials of at least 24 week duration, but also findings from small‐sized clinical ‘proof of principle’ studies. We conclude that GLP ‐1 RA and to a lesser extent DPP ‐4 inhibitors are promising agents with regard to their effects on body weight, blood pressure and lipids, which collectively ameliorate the cardiovascular‐risk profile and as such may have added value in the treatment of T2DM . However, large‐sized long‐term outcome studies are warranted to show the true added value of these agents in the treatment of patients with T2DM .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12050

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 46

Metadata

Authors
van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-01-21
Volume
15
Issue
7
Pages
593-606
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2044967663
Cited by
46
References
47
FWCI
4.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.